Categories: NewsNutrition

Theralogix Launches TheraCran(R) Max: Dual-Action Defense for Urinary Tract Health

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ROCKVILLE, MD / ACCESSWIRE / January 7, 2025 / Theralogix, a trusted leader in the nutritional supplement industry, proudly announces the launch of TheraCran® Max, a premium dual-action supplement designed to deliver daily urinary tract health support.* By combining content-certified cranberry extract with pure d-mannose, TheraCran Max provides a comprehensive, broad-spectrum approach to urinary health.*

TheraCran Max utilizes two scientifically backed ingredients that work in complementary ways. Each daily serving contains 40 mg of soluble proanthocyanidins (PACs) from the juice portion of a whole cranberry extract plus 1,000 mg of d-mannose. Cranberry PACs and d-mannose work in unique ways, both binding to bacteria to help flush it from the urinary tract.*

TheraCran Max is the only cranberry and d-mannose supplement independently tested and certified by NSF® International, ensuring content accuracy, purity, and safety. This rigorous third-party certification sets TheraCran Max apart in a market where assurance of quality and content accuracy are essential, but often absent.

As with all Theralogix products, TheraCran Max is manufactured in the USA in a GMP-compliant facility, spotlighting the company’s commitment to high-quality, evidence-based supplements. It is dye-free, gluten-free, and formulated specifically for anyone seeking reliable urinary tract health support.*

Theralogix is the #1 urologist-recommended supplement brand. When it comes to premium, research-backed nutritional supplements, Theralogix has set the standard for over two decades. TheraCran Max is now available for purchase on Theralogix.com and Amazon.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Contact Information

Shannon Mahon
smahon@theralogix.com
301.464.7210

SOURCE: Theralogix

View the original press release on accesswire.com

Staff

Recent Posts

Zepp Health Corporation Files 2024 Annual Report on Form 20-F

MILPITAS, Calif., April 25, 2025 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health" or the "Company")…

3 hours ago

Avvio Medical to Present Clinical Trial Results at the 2025 American Urological Association Annual Meeting

Moderated Interactive Poster Session to Feature AEROLITH RCT Data on Acoustic Enhancer Microbubble Cavitation with…

6 hours ago

HCA Healthcare Reports First Quarter 2025 Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the…

6 hours ago

HCA Healthcare Reports First Quarter 2025 Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the…

6 hours ago

HCA Healthcare Reports First Quarter 2025 Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results for the…

6 hours ago